Quest Diagnostics Inc Stock Price, News & Analysis

Quest Diagnostics (DGX) has secured a group purchasing agreement with Premier Inc. (PINC) for its laboratory stewardship solutions. This collaboration enables Premier members to access Quest's Lab Stewardship Enterprise at special pricing, facilitating improved healthcare delivery. The platform offers data analytics for healthcare organizations, tracking trends and identifying cost-saving opportunities. Quest aims to enhance care quality and operational efficiency as health systems face post-pandemic challenges. This agreement marks a significant enhancement in accessibility for Quest's innovative healthcare solutions.

Quest Diagnostics (NYSE: DGX) has completed its acquisition of LabCare Plus, the outreach laboratory services business of Summa Health. This acquisition enables Quest to enhance access to its extensive test menu and health plan relationships in Northeastern Ohio. Patients and physicians will benefit from improved diagnostic services and lower out-of-pocket costs. Testing will be provided by Quest’s laboratories in Twinsburg, Ohio, and Pittsburgh, Pennsylvania, serving areas previously serviced by LabCare Plus.

ConferMED has announced the provision of specialty eConsults to Federally Qualified Health Centers (FQHCs) in Texas, Maryland, Massachusetts, Florida, and Illinois, benefiting nearly 400,000 uninsured and underinsured patients. This initiative is supported by a $2.3M grant from the Quest Diagnostics Foundation as part of its Quest for Health Equity initiative. The program will enhance access to specialty care, potentially improving health outcomes for underserved communities. Fifteen health centers have already signed up, allowing primary care providers to consult with specialists across more than 40 specialties.

DermTech, Inc. (NASDAQ: DMTK) has formed an agreement with Sonora Quest Laboratories to enhance access to its non-invasive DermTech Melanoma Test in Arizona. The test, using Smart Stickers™, boasts over 99% reliability in ruling out melanoma, allowing patients to detect the disease early, significantly improving survival rates. This partnership will reduce unnecessary biopsies and healthcare costs while increasing the test's availability through Sonora Quest’s extensive provider network.

Quest Diagnostics (DGX) declared a quarterly cash dividend of $0.66 per share, payable on February 1, 2023. Shareholders of record will be eligible on January 18, 2023. This decision reflects the company's commitment to returning value to its shareholders while maintaining strong financial health and operational performance in the diagnostic information services sector.

On November 4, 2022, Quest Diagnostics (NYSE: DGX) launched three innovative fitness panels on questhealth.com. These panels are tailored for athletes at all levels and assess overall fitness by analyzing endurance, nutrition, hydration, energy, and hormone levels. The panels include the Essentials, Nutrition, and Elite Profiles, priced between $269 and $559. Results are available electronically within 7-14 days and may be covered by HSA/FSA. The initiative aims to empower athletes with actionable insights for enhanced performance and injury prevention.

Quest Diagnostics (NYSE: DGX) has been recognized in Fast Company's annual Brands That Matter list for its impactful Quest for Health Equity initiative. The initiative represents over $100 million allocated to reduce health disparities in underserved communities, addressing critical issues like heart disease and diabetes. The Fast Company list honors brands that create cultural impact and engagement, with Quest being acknowledged for its relevancy and emotional connection with the public. This highlights Quest's commitment to promoting health equity and community well-being.

Quest Diagnostics (NYSE: DGX) has announced the appointment of Jim Davis as CEO and President, succeeding Steve Rusckowski, who remains as Chairman until March 2023. This transition, initiated on February 3, 2022, aims to strengthen leadership following Rusckowski's decade-long service. Davis, who joined Quest in 2013, has led the company’s response to the COVID-19 pandemic. He emphasized a focus on growth, operational excellence, and advancing diagnostics to improve health outcomes.

Quest Diagnostics partners with Saint Louis University to launch an accelerated bachelor's degree program in medical laboratory science. This 16-month program aims to address the critical shortage of medical laboratory scientists, essential for performing diagnostic tests that inform patient diagnoses and treatments. Currently, the U.S. lacks enough graduates to meet the projected demand of 12,600 new jobs in this field by 2030. The collaboration ensures hands-on training and a potential 100% job placement rate for graduates, highlighting the urgent need for skilled professionals.